CD8A and leukemia: Previous studies have shown that anti-SLAMF6 antibody reduced the tumor burden in preclinical models of leukemia and melanoma through the activation of CD8 T cells17, and knock-out of Slamf6 in anti-melanoma CD8+ T cells improved therapeutic efficacy of adoptive T cell therapy23.